/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ultra-thin DSAEK delivers better results than standard DSAEK

    Multicenter randomized study finds strong visual results to support its use

    Take home message: Ultrathin Descemet’s stripping automated endothelial keratoplasty (DSAEK) is associated with faster visual recovery and better visual acuity in a study compared ultrathin with standard DSAEK.


    Patients treated with ultrathin Descemet’s stripping automated endothelial keratoplasty (DSAEK) achieve faster visual recovery and better visual outcomes compared with patients who undergo standard DSAEK, said Mor. M. Dickman, MD, University Eye Clinic Maastricht, the Netherlands.

    Dr. Dickman discussed the preliminary results of a Netherlands-based prospective randomized multicenter study that included four tertiary care medical centers. He and fellow researchers wanted to further investigate ultrathin DSAEK as DSAEK itself has become more popular because it is associated with less astigmatism, less ocular surface disease, less rejection, and greater tectonic stability compared with penetrating keratoplasty. However, visual acuity following standard DSAEK remains suboptimal, with only a small percentage of patients achieving 20/20 vision.

    The 65 patients who participated in the Netherlands study were randomly assigned to receive precut ultrathin DSAEK defined as 100 µm or less versus precut standard DSAEK, defined as thinner than 200 µm. The primary outcome measure was ETDRS best-corrected visual acuity (BCVA) at 12 months postoperatively. The secondary outcome measures were complication profile, quality of vision, and vision-related quality of life, Dr. Dickman said.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results